-
Arlington Capital Partners Issues Statement Regarding Stellant Systems, Inc.
Arlington Capital Partners Issues Statement Regarding Stellant Systems, Inc.
Share
WASHINGTON--(BUSINESS WIRE)--Arlington Capital Partners today issued the following statement:
“Stellant has never been stronger. The company is growing at over 20% per year, continues to push the boundaries of advanced RF technology, and is making strategic investments in long term production capacity. We respect the Department of Justice / Department of War process, complied fully with all requests, and we thank them for considering TransDigm’s interest in Stellant.”
Contacts
Media Contact
Ryan FitzGibbon
Pro-Arlington@prosek.com
Arlington Capital Partners
More News From Arlington Capital Partners
Highwater Bolsters its Leadership Team with Three Seasoned Hires
PORTLAND, Ore.--(BUSINESS WIRE)--Highwater (the “Company”), a leading provider of naval services to the U.S., Australian, and Allied navies, today announced the appointments of Dave Whitcomb as Chief Operating Officer and Scott McMurtry as Chief Financial Officer of Highwater, and Andy Davis as Chief Executive Officer of Highwater Australia. All three executives will report to Steve Zogas, Highwater’s global CEO. Highwater is a portfolio company of Arlington Capital Partners, a Washington, D.C....
AVS Bio, an Arlington Capital Partners Portfolio Company, Acquires Biorbyt Ltd.
NORWICH, Conn.--(BUSINESS WIRE)--AVS Bio (the “Company”), a leading global provider of critical inputs and services for the bioprocessing and biologics industries, today announced it has acquired Biorbyt Ltd. (“Biorbyt”), a global supplier of high-quality bio-reagents, antibodies, proteins, and other biomaterials for life science research. The acquisition significantly expands AVS Bio’s catalog of research products and global distribution capabilities through Biorbyt’s advanced ecommerce platfo...
Everest Clinical Research Expands Global Biometrics Capabilities with Acquisition of Firma Clinical Research's Data Services Business Unit
TORONTO--(BUSINESS WIRE)--Everest Clinical Research (“Everest”), a data-first, full-service clinical research organization, today announced the acquisition of the Biometrics and Data Services business unit of Firma Clinical Research (“Firma DS”), expanding Everest's global biometrics expertise and clinical data science capabilities. Everest is a portfolio company of Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private equity firm with extensive experience investing in regul...
